The mortality from lymphoma is high; thus, there is a great need to not only develop new therapeutic agents for this disease but to also further develop agents that have already shown promise in prior investigations. In early clinical trials, gallium nitrate (NSC15200) demonstrated significant clinical activity in lymphoma but its use in lymphoma was never rigorously pursued and information regarding its mechanisms of action has remained largely incomplete. There is now a renewed clinical interest in using gallium for lymphoma and clinical trials are in progress. The long-term objectives of this project are to optimally develop gallium compounds for the treatment of lymphoma by understanding its mechanisms of action. Our preliminary data suggest that the hemochromatosis (HFE) gene influences gallium uptake and cytotoxicity in lymphoblastoid cells and that gallium targets the mitochondria. HFE mutations, C282Y and H63D, occur with high frequency in the population.
Specific Aim 1 will further investigate the role of HFE [wild type (wt) and mutant] as modulators of transferrin receptor-targeted gallium uptake and cytotoxicity in lymphoma cells.
This Aim will investigate why lymphoblastic cells with the HFE C282Y mutation are more sensitive to gallium than cells with wt HFE. Studies will investigate the effects of HFE on gallium transport, gallium-induced apoptosis, gallium's action on iron homeostasis and ribonucleotide reductase.
Specific Aim 2 will examine the effects of gallium on the generation of reactive oxygen species (ROS), mitochondrial function, and apoptosis induction. The effect of HFE mutations on gallium's antineoplastic action will be investigated with immortalized cell lines developed from individuals with wt HFE and HFE mutations. Lymphoma cells transfected with an inducible HFE gene (wt or mutant) will also be utilized. Ga-67 and Fe-59-transferrin will be used for uptake studies. mRNA and protein levels of transferrin receptor, ferritin, and HFE will be measured by Northern blotting, ligand binding, immunoblotting and immunoassays. Iron regulatory protein-RNA binding and ribonucleotide reductase R2 subunit will be studied by bandshift assay and ESR spectroscopy, respectively. ROS in cells will be detected using fluorescent probes and HPLC. Mitochondria-targeted antioxidants will be employed to investigate the source of gallium-induced ROS production. Mitochondrial electron transport enzymes will be assayed by measuring oxygen consumption and ATP production in cells and isolated mitochondria using substrates and inhibitors. Assays will measure aconitase and glucose consumption and caspase activity. Our studies will provide new information regarding: a) the impact of HFE mutations on the response of lymphoma to gallium, and, b) the mechanism of action of gallium at the mitochondrial level.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA109518-02
Application #
7027683
Study Section
Special Emphasis Panel (ZRG1-DT (01))
Program Officer
Forry, Suzanne L
Project Start
2005-04-01
Project End
2009-02-28
Budget Start
2006-04-10
Budget End
2007-02-28
Support Year
2
Fiscal Year
2006
Total Cost
$262,963
Indirect Cost
Name
Medical College of Wisconsin
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Chitambar, Christopher R (2012) Gallium-containing anticancer compounds. Future Med Chem 4:1257-72
Chitambar, Christopher R (2010) Medical applications and toxicities of gallium compounds. Int J Environ Res Public Health 7:2337-61
Chitambar, Christopher R; Purpi, David P (2010) A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells. Leuk Res 34:950-3
Yang, Meiying; Chitambar, Christopher R (2008) Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells. Free Radic Biol Med 45:763-72
Yang, Meiying; Kroft, Steven H; Chitambar, Christopher R (2007) Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate. Mol Cancer Ther 6:633-43
Chitambar, Christopher R; Purpi, David P; Woodliff, Jeffrey et al. (2007) Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate. J Pharmacol Exp Ther 322:1228-36
Chitambar, Christopher R; Wereley, Janine P; Matsuyama, Shigemi (2006) Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition. Mol Cancer Ther 5:2834-43